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ﻫﺪﻑﺍﻟﺒﺤﺚ:ﻣﻘﺎﺭﻧﺔﻓﻌﺎﻟﻴﺔﻋﻼﺝﺍﻟﺘﻀﻴﻖﺍﻟﺒﻮﺍﺑﻲﺍﻟﻀﺨﺎﻣﻲﺍﻟﻄﻔﻠﻲﺑﺎﺳﺘﺨﺪﺍﻡﺳﻠﻔﺎﺕﺍﻷﺗﺮﻭﺑﻴﻦﻭﺍﻟﺘﺪﺧﻞﺍﻟﺠﺮﺍﺣﻲ،ﻣﻊﺇﺷﺎﺭﺓﺧﺎﺻﺔﺇﻟﻰﺗﺮﺍﺟﻊﺗﻀﺨﻢﺍﻟﺒﻮﺍﺏ.
ﻃﺮﻕﺍﻟﺒﺤﺚ:ﺗﻢﻣﻌﺎﻳﻨﺔ32ﺭﺿﻴﻌﺎﺗﺘﺎﺑﻌﺎﻳﻌﺎﻧﻮﻥﻣﻦﺗﻀﻴﻖﺍﻟﺒﻮﺍﺑﻲﻓﻲﺍﻟﻔﺘﺮﺓﻣﻦﻳﻨﺎﻳﺮ2008ﺇﻟﻰﻳﻮﻧﻴﻮ2011،ﻭﺗﻢﺍﺧﺘﻴﺎﺭ28ﺣﺎﻟﺔﻣﻨﻬﻢﻋﺸﻮﺍﺋﻴﺎ.ﻭﺷﺨﺼﺖﺟﻤﻴﻊﺍﻟﺤﺎﻻﺕ
ﺑﺎﻷﺷﻌﺔﺍﻟﺼﻮﺗﻴﺔ.ﺗﻜﻮﻥﺍﻟﻌﻼﺝﺍﻟﻄﺒﻲﻣﻦﺣﻘﻦﺍﻷﺗﺮﻭﺑﻴﻦﻋﻦﻃﺮﻳﻖﺍﻟﻮﺭﻳﺪ0,01ﻣﺠﻢ/ﻛﺠﻢﻛﻞ4ﺳﺎﻋﺎﺕ،ﺗﻼﻫﺎﺇﻋﻄﺎﺀﺍﻷﺗﺮﻭﺑﻴﻦﻋﻦﻃﺮﻳﻖﺍﻟﻔﻢ0,02ﻣﺠﻢ/ﻛﺠﻢﻛﻞ4ﺳﺎﻋﺎﺕ،ﺃﻣﺎ
ﺍﻟﻌﻼﺝﺍﻟﺠﺮﺍﺣﻲﻓﻜﺎﻥﺑﻄﺮﻳﻘﺔ"ﺭﺍﻣﺴﺘﺪ"ﺍﻟﻤﻌﺘﺎﺩﺓﻟﺒﻀﻊﻋﻀﻠﺔﺍﻟﺒﻮﺍﺏﺗﺤﺖﺍﻟﺘﺨﺪﻳﺮﺍﻟﻜﺎﻣﻞ.ﺗﻢﻗﻴﺎﺱﺍﻻﺳﺘﺠﺎﺑﺔﻟﻠﻌﻼﺟﻴﻦﻋﻦﻃﺮﻳﻖﺍﻟﺘﺤﺴﻦﺍﻟﺴﺮﻳﺮﻱ،ﻭﺯﻳﺎﺩﺓﺍﻟﻮﺯﻥ،ﻭﻗﻴﺎﺱﺳﻤﻚ
ﻋﻀﻠﺔﺍﻟﺒﻮﺍﺏﻭﻃﻮﻝﻗﻨﺎﺓﺍﻟﺒﻮﺍﺏﻋﻦﻃﺮﻳﻖﺍﻷﺷﻌﺔﺍﻟﺼﻮﺗﻴﺔ.
ﺍﻟﻨﺘﺎﺋﺞ:ﺗﻢﻋﻼﺝ14ﻃﻔﻼﺭﺿﻴﻌﺎﺑﺎﻟﻌﻼﺝﺍﻟﻄﺒﻲﻭ14ﺑﺎﻟﻌﻼﺝﺍﻟﺠﺮﺍﺣﻲ.ﺃﺩﻯﺍﻟﻌﻼﺝﺍﻟﻄﺒﻲﺇﻟﻰﺍﻟﺸﻔﺎﺀﺍﻟﺘﺎﻡﻟﻌﺪﺩ8ﺣﺎﻻﺕﻣﻦﺑﻴﻦ12ﺭﺿﻴﻌﺎ)%66,6(،ﺑﻴﻨﻤﺎﺍﻟﻌﻼﺝﺍﻟﺠﺮﺍﺣﻲ
ﻛﺎﻥﻧﺎﺟﺤﺎﻟﺠﻤﻴﻊﺍﻟﺤﺎﻻﺕﻭﻋﺪﺩﻫﻢ14ﺭﺿﻴﻌًﺎ)%100;0.05<p(.ﻛﺎﻧﺖﻓﺘﺮﺓﺍﻹﻗﺎﻣﺔﺑﺎﻟﻤﺴﺘﺸﻔﻰ10±2ﻳﻮﻣﺎﻓﻲﺣﺎﻝﺍﻟﻌﻼﺝﺍﻟﻄﺒﻲﻭ3±1ﻳﻮﻣﺎﻟﻠﻌﻼﺝﺍﻟﺠﺮﺍﺣﻲ)0.0001=p(.
ﺍﻻﺳﺘﻨﺘﺎﺟﺎﺕ:ﻳﺘﻔﻮﻕﺍﻟﻌﻼﺝﺍﻟﺠﺮﺍﺣﻰﻋﻠﻰﺍﻟﻌﻼﺝﺍﻟﻄﺒﻲﻓﻲﺣﺎﻻﺕﺍﻟﺘﻀﻴﻖﺍﻟﺒﻮﺍﺑﻲﺍﻟﻀﺨﺎﻣﻲﺍﻟﻄﻔﻠﻲ.ﻭﻟﻜﻦﻣﻌﺪﻝﻧﺠﺎﺡﺍﻟﻌﻼﺝﺍﻟﻄﺒﻲﺑﺎﺳﺘﺨﺪﺍﻡﺳﻠﻔﺎﺕﺍﻷﺗﺮﻭﺑﻴﻦﻳﺒﺮﺭﺍﺳﺘﺨﺪﺍﻣﻪ
ﻟﻠﺮﺿﻊﻟﻤﻦﻟﺪﻳﻬﻢﻣﻮﺍﻧﻊﻃﺒﻴﺔﻟﻠﻌﻼﺝﺍﻟﺠﺮﺍﺣﻲﻭﻛﺬﻟﻚﻋﻨﺪﻣﺎﻳﻔﻀﻞﺍﻟﻮﺍﻟﺪﻳﻦﺍﻟﻌﻼﺝﺍﻟﻄﺒﻲ
ﺍﻟﻜﻠﻤﺎﺕﺍﻟﻤﻔﺘﺎﺣﻴﺔ:ﺍﻟﻌﻼﺝﺑﺎﻷﺗﺮﻭﺑﻴﻦ;ﺿﻴﻖﺍﻟﺒﻮﺍﺏ;ﺑﻀﻊﻋﻀﻠﺔﺍﻟﺒﻮﺍﺏ;ﺍﻟﺠﺮﺍﺣﺔ.
Abstract
Objective: To compare the efficacy of treatment of infantile hypertrophic pyloric stenosis with atropine sulfate and by surgery, with
special reference to regression of pyloric hypertrophy.
Methods: Thirty-two consecutive infants with pyloric stenosis were seen between January 2008 and June 2011, and 28 cases were
enrolled randomly. The diagnosis in all infants was confirmed by an abdominal ultrasound. Medical treatment consisted of intra-
venous atropine at 0.01 mg/kg every 4 h, followed by oral atropine at 0.02 mg/kg every 4 h. Surgical treatment consisted of standard
Ramstedt’s pyloromyotomy under general anesthesia. The response to the two treatments was gauged from clinical improvement,
weight gain and ultrasonic measurement of pyloric muscle thickness and pyloric canal length.
Results: Fourteen infants were treated medically and 14 were given surgical treatment. Medical treatment resulted in complete
cure in 8 of 12 infants (66.6%), whereas surgical treatment was successful in all 14 infants (100%; p< 0.05). The mean length of
hospital stay was 10 ± 2 days for medically treated infants and 3 ± 1 days for those treated surgically (p= 0.0001).
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Conclusion: Surgical treatment is superior to medical treatment in cases of infantile pyloric stenosis. The success rate of medical
treatment with atropine sulfate nevertheless justifies its administration to infants in whom surgery is contraindicated and when med-
ical treatment is preferred by the parents.
Keywords: Atropine therapy; Pyloric stenosis; Pyloromyotomy; Surgery
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Infantile hypertrophic pyloric stenosis is an acute abdominal
emergency and is the most common cause of non-bilious vom-
iting in infancy.1 Its incidence is 2–4 per 1000 live births,2 and
the risk is four times higher in boys than girls. The pylorus
hypertrophies after birth and causes progressive gastric outlet
obstruction, infants most commonly presenting this are be-
tween 2 and 6 weeks of age.3 The typical presentation is with
projectile and non-bilious vomiting, which, if unrelieved, leads
to progressive weight loss, dehydration and metabolic
abnormalities.4
The exact etiology and pathogenesis are unknown, but the
reason for clinical presentation is hypertrophy of the circular
muscle layer of the pylorus, which causes gastric outlet
obstruction. The diagnosis is usually clinical; it is based on a
suggestive history and confirmed by palpation of the hypertro-
phied pylorus, or ‘olive’, which has a positive predictive value
of 99%.5,6 Recently, there has been an increasing reliance on
imaging for diagnosis of pyloric stenosis.
The standard surgical technique is Ramsestdt’s pyloromy-
otomy, and this is still the treatment for infantile hypertrophic
pyloric stenosis. Various surgical approaches have been de-
scribed, including right upper quadrant transverse incision,
umbilical incision, supraumbilical skin-fold incision and, re-
cently, the laparoscopic approach. Each has its merits and
demerits.
Medical treatment with atropine sulfate has been proposed
as an alternative to surgical treatment. Atropine sulfate is a
cholinergic drug with strong anti-muscarinic effects, which
temporarily suppresses spastic contractions of pyloric muscle
in pyloric stenosis.7,8 The clusters of tonic and phasic pyloric
contractions characteristic of infantile hypertrophic pyloric
stenosis are transiently abolished by an intravenous atropine
injection of 0.01 mg/kg.9 Initial reports on the use of this meth-
od, however, did not validate its use as a treatment option, in
view of the reported low success rate of 50%.7,10
Recently, however, researchers in India reported a success
rate of 96% with medical treatment,11 which has encouraged
other researchers to review the treatment of infantile hypertro-
phic pyloric stenosis with atropine sulfate. The objective of this
study was to compare medical and surgical treatment of this
condition for success rate, efficacy and complications.
Materials and Methods
A prospective study was conducted in the Pediatric Surgery
Department during the period January 2008 to June 2011.
Thirty-two consecutive infants (29 boys and 3 girls) in whom
infantile hypertrophic pyloric stenosis was diagnosed after pre-
sentation at the emergency department fulfilled the following
diagnostic criteria: a classical history of pyloric stenosis (fre-
quent non-bilious projectile vomiting), pyloric muscle thick-
ness P4 mm and pyloric canal length P15 mm on
ultrasonography. The patients were randomized to medical
or surgical treatment by the sealed envelope method. Both
modalities of treatment and the aim of the study were ex-
plained to the parents before they gave consent for their in-
fants to participate in the study.
Four cases were excluded from randomization. The parents
of three infants refused randomization and selected medical
treatment. One of the infants improved on this treatment,
while the other two showed partial response and were shifted
to surgery. The fourth infant developed aspiration pneumonia
and surgery was delayed; meanwhile, he received atropine ther-
apy for 10 days. He improved, tolerated oral feeding well and
was discharged on oral atropine for another 3 weeks. The
remaining 28 infants were randomly assigned to medical or
surgical treatment.
Medical treatment consisted of atropine sulfate adminis-
tered intravenously at a dose of 0.01 mg/kg every 4 h, 5 min
before feeding. The heart rate was monitored during atropine
injection. Infants in whom intravenous atropine was success-
ful, i.e. vomiting ceased, were shifted to oral atropine at a
dose of 0.02 mg/kg every 4 h before feeding.8 They were dis-
charged from the hospital when vomiting was controlled with
oral atropine and they tolerated oral feeding of 150 ml/kg;
atropine was then continued at home for 1 month. Medical
treatment was considered ineffective when the infant failed
to tolerate oral feeding and vomiting persisted 48–72 h after
the start of intravenous atropine or vomiting recurred after
starting oral atropine. Non-responders were shifted to surgical
treatment. Surgical treatment consisted of classical Ram-
stedt’s pyloromyotomy under general anesthesia (Figure 1).
In cases of mucosal injury, simple closure was done with an
omental patch. The wound was then closed in layers. Oral
feeding was allowed on the same day in cases with no mucosal
injury and postponed for at least 48 h in cases complicated by
mucosal injury.
Response to either surgical or medical treatment was as-
sessed clinically on the basis of cessation of vomiting, tolerat-
ing oral intake and gaining weight, and radiologically by
ultrasonographic measurements of pyloric muscle thickness
and pyloric canal length. Complete response was defined as
sustained clinical and sonographic response after cessation of
treatment. Partial response was defined as incomplete response
to intravenous therapy or response to intravenous therapy but
recurrence of vomiting on start of oral therapy. All infants
were followed for 1 year to evaluate vomiting, weight gain
Figure 2: Before treatment: high-resolution ultrasound showing
enlarged, thick pylorus (length, 25 mm; thickness, 4.4 mm).
Figure 3: After treatment: high-resolution ultrasound showing a
short pyloric channel with a length of 11.5 mm and muscle
thickness of 2.9 mm.
Figure 1: Pyloromyotomy.
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done in all treated cases 6 weeks after the end of treatment to
confirm radiological improvement.
The treated infants in the two groups were compared for
success rate, incidence of complications and length of hospital
stay.
Statistical analysis
Data were collected and entered with SPSS (version 13). Quan-
titative data are shown as means and standard deviations.
Qualitative data are expressed as frequencies and percentages.
The Fisher exact test was used to compare treatment success
and complication rates of surgical versus medical treatment.
Student’s t-test was used to assess regression of pyloric muscle
thickness and pyloric canal length, as well as the mean length
of hospital stay in the two groups. P values were considered
significant if 60.05.
Results
The group treated medically consisted of 13 males and 1 fe-
male with a mean age of 28 days (SD 7) and a mean weight
of 3.4 kg (SD 0.8). The group treated surgically consisted of
12 males and 2 females with a mean age of 36 days (SD, 5)
and a mean weight of 3.6 kg (SD, 0.4).
Surgical treatment was successful in all 14 cases. In the
medical group, complete response was found in 8 of the 12 in-
fants who completed the regime (66.7%); partial response was
observed in 2 cases and no response in 2 cases. These last 4
cases underwent surgical treatment. Two were withdrawn from
the study because of loss of follow-up after discharge from
hospital. The difference between medical and surgical treat-
ment was statistically significant (p< 0.02).
The mean length of hospital stay was 10 days (SD, 2) after
medical treatment and 3 days (SD, 1) after surgeryTable 1: Ultrasonographic measurements before and 6 weeks after tre
Treatment Pyloric muscle thickness (mm) (mean ± SD)
Before After p
Surgery (n= 14) 5.29 ± 1.07 3.5 ± 1.09 0.
Atropine (n= 8) 4.75 ± 0.71 2.88 ± 0.64 0.(p< 0.0001). Complications occurred in none of the medically
treated infants and in 2/14 (14.3%) of the surgically treated
group (p= 0.19). One infant who had undergone surgery
had mucosal perforation during pyloromyotomy, and the
other had a wound infection. There were no recurrences in
either group. The ultrasonographic responses to treatment
are shown in Table 1 and Figures 2 and 3.
Discussion
Surgical treatment was clearly superior to medical treatment
with regard to response and was also associated with a shorter
hospital stay. Complications, however, occurred more often in
the surgically treated group. Although pyloromyotomy is a
safe curative procedure, it has its risks. Hulka et al.12 reported
0.1% mortality, 4% intraoperative complications and 6%atment.
Pyloric muscle length (mm) (mean ± SD)
Before After p
0002 23.57 ± 3.57 20.29 ± 3.02 0.014
0001 22.75 ± 3.28 18.13 ± 3.26 0.013
postoperative complications, such as bleeding, mucosal perfo-
ration and wound infection. Mucosal perforation commonly
results from extending the myotomy beyond the pyloric–duo-
denal junction. Pranikoff et al.13 found that the risk for muco-
sal perforation was 0.5% when pyloromyotomy was
performed by a pediatric surgeon. In our study, mucosal per-
foration occurred in one case and wound infection in another.
Although there has been some concern about side-effects of
atropine, no serious complications have been reported. Nagita
et al.10 reported only mild facial flushing, increased alanine
aminotransferase activity and tachycardia. We observe no
complications in our medically treated infants. Although the
complication rate in the surgical group was higher than that
in the medical group in this study, the difference was not sta-
tistically significant. Other concerns with atropine treatment
are the length of hospital stay and the necessity to continue
oral atropine medication after being discharged home, which
requires good compliance by the parents. Kawahara and co-
workers14 reported that the duration of hospital stay for pa-
tients treated surgically was significantly shorter than that of
the atropine group (5 days [4–29] vs 13 [6–36] days,
p< 0.001). We found similar results: the hospital stay for
our surgical group was 3 ± 1 days and that of the medically
treated group was 10 ± 2 (p= 0.0001). Responding medically
treated infants have to continue oral atropine at home for
about 1 month; however, this long duration of medical treat-
ment may be accepted in order to avoid the risks associated
with surgery and anesthesia.
The success rate was 66.7% in the medical group and 100%
in the surgical group in our study. The rate for the medical
group was lower than those reported by Singh et al.11 and Ka-
suko et al.15 (96%), Kawahara et al.14 (87%) and Meissner
et al.16 (75.8%). This may be due to the small number of in-
fants in the medical group who completed the study, use of dif-
ferent doses of atropine and different durations of intravenous
regimens by other researchers and the fact that we did not
escalate the dose of intravenous atropine to overcome unre-
sponsiveness, as done by other researchers.10 No obvious clin-
ical or radiological features were found for the infants who
failed to respond to medical treatment and those who re-
sponded in this study.
Currently, upper abdominal ultrasound is the imaging
modality of choice in pediatric centers. The success and reli-
ability of this modality depend to a certain extent on the oper-
ator and his or her experience. Ultrasound is performed after
feeding the infant dextrose solution to dilate the fundus, which
improves the image quality.3 The length of the pyloric channel
and the thickness of the pyloric muscle are the quantitative
parameters in the longitudinal view. The classical target sign
is seen in the transverse view. Although conventional ultra-
sound is widely used, high-resolution endoscopic ultrasound
can be performed by placing the probe along small endoscopes
when the luminal diameter is limited, and the muscle thickness
is easily seen.17
Regression of pyloric muscle hypertrophy has been docu-
mented ultrasonographically in patients treated surgically
and medically. A recent study concluded that the initial change
was shortening of the pyloric canal followed by thinning of the
muscular layer.18 Sauerbrei and Paloschi19 found that the mus-
cle thickness and the pyloric diameter and length fell into the
normal range within 6 weeks of pyloromyotomy. Yoshizawa
et al.20 demonstrated that, after pyloromyotomy, the pylorus
changes significantly within 3 days and returns to normal with-
in 5 months. In other studies, the pylorus returned to normal
2–12 weeks after surgery and after 3–15 months in medically
treated infants.7,21,22 Our finding in the medically treated pa-
tients is similar to that of Nagita et al.,10 who reported a return
to normality after 4–12 months. Yamataka et al.,23 however,
reported that the time to normalization of pyloric muscle
thickness was not significantly different between patients
undergoing pyloromyotomy and those treated with atropine.
In our study, significant regression of pyloric muscle thickness
and shortening of the pyloric canal length were observed with-
in 6 weeks in both medically and surgically treated infants,
but complete normalization did not occur during this short
period. Nevertheless, the presence of asymptomatic hypertro-
phied pylorus for a limited time may not be of clinical signif-
icance.8 In our study, there was one case of aspiration
pneumonia, and in two cases the parents chose to start with
medical treatment.
Although both surgical and medical options are valuable,
time-tested treatment modalities in the treatment of infantile
hypertrophic pyloric stenosis, surgery is still the standard
treatment worldwide. We consider that surgery is superior
to medical treatment; however, there is a place for medical
treatment in the management of pyloric stenosis, such as con-
traindication to surgery and parents’ choice of a non-surgical
modality. Parents’ compliance with follow-up of medical
treatment is, however, mandatory for a good response to
treatment.
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